Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden

OBJECTIVES: While previous cost-effectiveness studies on pembrolizumab in stage IV non-small cell lung cancer (NSCLC) have found these regimens to be cost-effective, their reliance on randomized controlled trial (RCT) data with strict inclusion criteria limits generalizability to patients with comor...

Descripción completa

Detalles Bibliográficos
Autores principales: Criss, Steven D., Palazzo, Lauren, Watson, Tina R., Paquette, Adelle M., Sigel, Keith, Wisnivesky, Juan, Kong, Chung Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988966/
https://www.ncbi.nlm.nih.gov/pubmed/31995619
http://dx.doi.org/10.1371/journal.pone.0228288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988966/
https://www.ncbi.nlm.nih.gov/pubmed/31995619
http://dx.doi.org/10.1371/journal.pone.0228288

Ejemplares similares